MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4088/jcp.08m04949gre

Медицинская библиотека · The Journal of clinical psychiatry · 2009

Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial.

Stein Murray B, Ravindran Lakshmi N, Simon Naomi M, Liebowitz Michael R, Khan Arifulla, Brawman-Mintzer Olga, Lydiard R Bruce, Pollack Mark H

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

This multicenter, double-blind, placebo-controlled, 2-arm, parallel-group study was carried out to determine the effectiveness and safety of the novel anticonvulsant levetiracetam for the treatment of generalized social anxiety disorder (GSAD).

METHOD: After a 1-week, single-blind, placebo run-in period, 217 adult outpatients meeting DSM-IV criteria for social anxiety disorder, generalized type, were randomly assigned (1:1) to 12 weeks of double-blind treatment with either levetiracetam (n = 111) or placebo (n = 106). Participants were required to have scores of >or= 60 on the Liebowitz Social Anxiety Scale (LSAS) and a total score of <or= 17 on the 17-item Hamilton Depression Rating Scale (HDRS). The primary outcome measure was mean change from baseline on LSAS total score. Levetiracetam was initiated at 250 mg/d and flexibly titrated up to a maximum dose of 3,000 mg/d (1,500 mg bid). Dosage was held stable for the last 6 weeks of treatment. The study was conducted from September 2003 to June 2004.

RESULTS

No statistically significant difference was found between the adjusted mean changes in LSAS score for levetiracetam (-24.4) and placebo (-28.7) using an efficacy intent-to-treat, last- observation-carried-forward analysis. Rates of response (>or= 30% reduction in LSAS score) were similar with 41.3% (levetiracetam) and 46.6% (placebo). No significant between-group differences were found on secondary outcome measures, which included changes in Sheehan Disability Scale, Clinical Global Impression of Change, and HDRS scores.

CONCLUSIONS

Although well-tolerated, levetiracetam failed to separate from placebo in this trial for the treatment of moderate to severe GSAD.

Для цитирования: Stein Murray B, Ravindran Lakshmi N, Simon Naomi M, Liebowitz Michael R, Khan Arifulla, Brawman-Mintzer Olga, Lydiard R Bruce, Pollack Mark H. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial.. The Journal of clinical psychiatry. 2009. DOI: 10.4088/jcp.08m04949gre.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.